Skip to main content

Med BioGene and Duke to Jointly Develop Biomarkers for Lymphoma, Leukemia

NEW YORK (GenomeWeb News) – Med BioGene this week said it has entered into a research collaboration and option agreement with Duke University to further develop and validate genetic biomarkers for lymphoma and leukemia.
 
Under the terms of the collaboration, which will use MBI’s gene expression-profiling system, Duke will provide MBI a certain number of samples from patients with clinically confirmed lymphoma and leukemia for genetic analysis.
 
Duke and MBI will analyze those results, and Duke will grant MBI an option to acquire exclusive worldwide licensing rights to the intellectual property developed under the collaboration.
 
MBI will reimburse Duke for certain expenditures, and then pay undisclosed royalties to Duke on revenue received from product sales. Duke will be entitled to publish the results of the research, subject to review by MBI.
 
Financial terms of the agreement were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.